CHOSA Oncology AB published results from the prospective phase 2 study of LiPlaCis (a liposomal formulation of cisplatin) in previously heavily treated patients with metastatic breast cancer as the abstract is being released on the ASCO website on May 25, 2023. This patient group was tested using the diagnostic tool Drug Response Prediction, which is a 205 mRNA biomarker signature, that assesses whether the patient is likely to respond to cisplatin treatment - or not. The results show that patients who get high scores in the DRP reading (DRP 80 +) are the only ones that respond and show 2.5x longer median PFS (Progression Free Survival).

This metastatic breast cancer group, which has received several other treatments in the past, presents a major challenge as they may have developed 'treatment resistance'. Many times, physicians would like to choose cisplatin treatment, but opt out of this as it has a strong side effect profile. DRP®?

is proprietary to and a registered trademark of Allarity Therapeutics. These data are from a clinical study previously run by Allarity (formerly Oncology Venture). ChOSA Oncology AB has licensed worldwide rights to LiPlaCis and its DRP®?

companion diagnostic from Allarity Therapeutics Inc.